| Literature DB >> 29887180 |
David Vivas1, Inmaculada Roldán2, Raquel Ferrandis3, Francisco Marín4, Vanessa Roldán5, Antonio Tello-Montoliu4, Juan Miguel Ruiz-Nodar6, Juan José Gómez-Doblas7, Alfonso Martín8, Juan Vicente Llau9, María José Ramos-Gallo10, Rafael Muñoz11, Juan Ignacio Arcelus12, Francisco Leyva13, Fernando Alberca14, Raquel Oliva15, Ana María Gómez16, Carmen Montero17, Fuat Arikan18, Luis Ley19, Enrique Santos-Bueso20, Elena Figuero21, Antonio Bujaldón22, José Urbano23, Rafael Otero24, Juan Francisco Hermida25, Isabel Egocheaga26, José Luis Llisterri27, José María Lobos28, Ainhoa Serrano29, Olga Madridano30, José Luis Ferreiro31.
Abstract
During the last few years, the number of patients receiving anticoagulant and antiplatelet therapy has increased worldwide. Since this is a chronic treatment, patients receiving it can be expected to need some kind of surgery or intervention during their lifetime that may require treatment discontinuation. The decision to withdraw antithrombotic therapy depends on the patient's thrombotic risk versus hemorrhagic risk. Assessment of both factors will show the precise management of anticoagulant and antiplatelet therapy in these scenarios. The aim of this consensus document, coordinated by the Cardiovascular Thrombosis Working Group of the Spanish Society of Cardiology, and endorsed by most of the Spanish scientific societies of clinical specialities that may play a role in the patient-health care process during the perioperative or periprocedural period, is to recommend some simple and practical guidelines with a view to homogenizing daily clinical practice.Entities:
Keywords: Antiagregación; Anticoagulación; Anticoagulation; Antiplatelet; Antithrombotic; Antitrombótico; Cirugía; Surgery
Mesh:
Substances:
Year: 2018 PMID: 29887180 DOI: 10.1016/j.rec.2018.01.029
Source DB: PubMed Journal: Rev Esp Cardiol (Engl Ed) ISSN: 1885-5857